Buradasınız

Anasayfa » Content

Adenozinin Plazma Homosistein ve Bazı Biyokimyasal Parametreler Üzerine Etkileri

The effects of adenosine on plasma homocysteine levels and some other biochemical parameters

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Adenosine has an important role in (physiology and pathological cardiovascular aspects) the pathogenesis of cardiovascular diseases. Some clinical and epidemiological studies revealed the importance of high plasma homocysteine levels in the progression of atherosclerosis. It was also shown that high level of plasma homocysteine is an independent risk factor for coronary, cerebrovascular and peripheral occlusive vascular diseases. In this study we investigated the effects of exogenous adenosine administration on plasma homocysteine levels and some other biochemical parameters. Twenty adult male Balb-c mice were included to the study. To the experimental group (n=10) intraperitoneal 0.2 ml, 30 mg/kg adenosine was applied twice in a day for three consecutive days. To the control group (n=10) intraperitoneal 0.2 ml 0.09% NaCl was applied twice in a day for 3 consecutive days. After blood was collected into heparinized tubes under the ether anaesthetized mice by intracardiac puncture. Plasma homocysteine, total cholesterol, HDL-cholesterol, triglyceride, C-reactive protein, alkaline phosphatase, aspartat amino transferase, alanin amino transferase, gama-glutamyl transferase were measured. LDL-cholesterol and VLDL-cholesterol levels were calculated by using appropriate formulas. Differences between the groups were analysed by Mann-Whitney U test. There was no difference in plasma homocysteine and other biochemical parameters between both groups. These results show that exogenous adenosine application did not effect the plasma homocysteine, total cholesterol, HDL-cholesterol, triglyceride, C-reactive protein, alkaline phosphatase, aspartat amino transferase, alanin amino transferase, gama-glutamyl transferase, LDL-cholesterol and VLDL-cholesterol levels.
Bookmark/Search this post with
Abstract (Original Language): 
Adenozin kardiyovasküler hastalıkların fizyolojisi ve gelişiminde önemli bir role sahiptir. Bazı klinik ve epidemiyolojik çalışmalar ateroskleroz gelişiminde yüksek plazma homosistein düzeylerinin önemini ortaya koymuştur. Yüksek plazma homosistein düzeylerinin koroner, kardiyovasküler ve periferik damar hastalıklarında bağımsız bir risk faktörü olduğu da gösterilmiştir. Bu çalışmada, ekzojen olarak adenozin verilmesinin plazma homosistein düzeylerine ve bazı biyokimyasal parametreler üzerine olan etkisi araştırıldı. 20 yetişkin Balb-c cinsi sıçan çalışmaya dahil edildi. Deney grubuna (n=10) 0,2 ml intraperitoneal yolla 3 gün (2 kez/gün) 30 mg/kg adenozin verildi. Kontrol grubuna (n=10) ise 0.2 ml 0.09% NaCl aynı yolla uygulandı. Eter anestezisi altında intrakardiyak yoldan alınan kan örnekleri heparinli tüplere konuldu. Plazma homosistein, total kolesterol, HDL-kolesterol, trigliserid, C-reactif protein, alkalen fosfataz, aspartat amino transferaz, alanin amino transferaz, gama-glutamil transferaz düzeyleri ölçüldü. LDL-kolesterol and VLDL-kolesterol düzeyleri uygun formüllerle hesaplandı. Gruplar arasındaki farklılıklar Mann-Whitney U testi ile analiz edildi. Gruplar arasında plazma homosistein ve diğer biyokimyasal parametrelerde anlamlı farklılık bulunamadı. Bu sonuçlar, eksojen olarak adenozin uygulanmasının plazma homosistein, total kolesterol, HDL-kolesterol, trigliserid, C-reactif protein, alkalen fosfataz, aspartat amino transferaz, alanin amino transferaz, gama-glutamil transferaz, LDL-kolesterol ve VLDL-kolesterol düzeylerini etkilemediğini göstermektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-adenozinin-plazma-homosistein-bazi-biyokimyasal-parametreler-uzerine-etkileri.pdf
  • 4
25-29
  • Turkish

REFERENCES

References: 

1. Osswald H, Muhlbauer B, Vallon V. Adenosine and tubuloglomerular feedback. Blood Purif 1997;15:243-52.
2. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects ofpreconditioning. Cardiovasc Res 1993;27: 3-8.
3. Ely S, Berne R. Protective effects ofadenosine in myocardialischemia. Circulation 1992;85:893-904.
4. Ubbink JB, Vermaak WJ, Van Der Merwe A, Becker PJ. The effect ofblood sample aging and food consumption on plasma total homocysteine levels. Clin ChimActa 1992;207: 119-28.
5. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease, Francis DB (Eds), Marcel Dekker, 1992, pp 183-236.
6. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. Ann Pharmacother 2000;34:57-65.
7. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B et al. LDL cholesterol upregulates synthesis ofasymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
8. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine P-synthase-deficientmice. Circ Res 2001;88: 1203-9.
9. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as
a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
10. Pruefer D, Scalia R, Lefer AM. Homocysteine provokes leukocyte-endothelium interaction by downregulation ofnitric oxide. Gen Pharmacol 1999;33:487-98.
11. Matthias D, Becker CH, Riezler R, Kindling P. Homocysteine induced arteriosclerosis-like alterations ofthe aorta in normotensive and hypertensive rats following application ofhigh doses ofmethionine. Atherosclerosis 1996;122:201-16.
12. Brattström L, Wilcken D. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr2000;72:315-23.
13. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002;106:1275-81.
14. Sciotti VM, Van Wylen DG. Attenuation ofischemia-induced extracellular adenosine accumulation by homocysteine. J Cereb Blood Flow Metab 1993;13:208-13.
15. Schrader J, Schutz W, Bardenheuer H. Role ofS-adenosylhomocysteine hydrolae in adenosine metabolism in mammalian heart. Biochem J 1981;196:65-70.
16. Biaggioni I, Mosqueda-Garcia R. Adenosine in cardiovascular homeostasis and the pharmacologic control ofits activity. In Hypertension, Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM (eds), 2nd ed., Raven, 1995, pp 1125-40.
17. Ethier MF, Chander V, Dobson JG. Adenosine stimulates proliferation ofhuman endothelial cells in culture. Am J Physiol 1993;265:131-8.
18. Mccully KS. Vascular pathology ofhomocysteinemia: implications for the pathogenesis ofarteriosclerosis. AmJPathol 1969;56:111-28.
19. Vollset SE, Refsum H, Tverdal A, Nygard O, Nordrehaug JE, Tell GS. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001;74:130-6.
20. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997;11:1157-68.
21. Lenz SR, Sobet CG, Piegors DJ, Bhopaktar MY, Faraci FM, Manilow MR. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest
1996;98:24-9.
22. Engler R. Adenosine: The signal oflife? Circulation 1991;84:951-4.
23. Belardinelli L, Linden J, Berne RM. The cardiac effects ofadenosine. Prog Cardiovasc Dis 1989;32:73-97.
S.D.Ü. Tıp pak.
Derg
. 2007:14(4)/ 25-29
Turgut,
Adenosin
e and homocysteine
29
24. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001;52:25-39.
25. Deussen A. Adenosine—the missing link to understanding homocysteine pathogenicity or more smoke onthehorizon? Cardiovasc Res 2003;59:259-61.
26. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union ofPharmacology. XXV. Nomenclature and classification ofadenosine receptors. Pharmacol Rev 2001; 53:527-52.
27. Riksen NP, Rongen GA, Blom HJ, Russel FGM, Boers GHJ, Smits P. Potential role for adenosine in the pathogenesis ofthe vascular complications of hyperhomocysteinemia. Cardiovascular Research 2003;56:271-6.
28. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992;85:659-65.
29. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res 1993;27:68-76.
30. Dubey RK, Gillespie DG, Jackson EK. A(2B) adenosine receptors stimulate growth ofporcine and rat arterial endothelial cells. Hypertension 2002;39:530-5.
31. Ueland PM. Pharmacological and biochemical aspects ofS-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev 1982;34:223-53.
32. Hultberg B, Andersson A, Isaksson A. Hypomethylation as a cause ofhomocysteine-induced cell damage in human cell lines. Toxicology 2000;147:69-75.
33. Deussen A, Borst M, Schrader J. Formation of S-adenosylhomocysteine in the heart. I: An index offree intracellular adenosine. Circ. Res 1988;63:240-9.
34. Liu S, Wnuk SF, Yuan C, Robins MJ, Borchardt RT. Adenosine-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase. J Med Chem
1993;36:883-7.
35. Mehdi S, Jarvi ET, Koehl JR, McCarthy JR, Bey P. The mechanism ofinhibition of S-adenosyl-L-homocysteine hydrolase by fluorine-containing adenosine analogs. J Enzyme Inhib 1990;4:1-13.

Thank you for copying data from http://www.arastirmax.com